Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$2.94 - $4.77 $2.2 Million - $3.58 Million
-749,740 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$4.07 - $5.3 $292,689 - $381,144
-71,914 Reduced 8.75%
749,740 $3.37 Million
Q3 2021

Nov 15, 2021

SELL
$4.7 - $7.24 $59,248 - $91,267
-12,606 Reduced 1.51%
821,654 $3.99 Million
Q2 2021

Aug 16, 2021

SELL
$6.81 - $10.93 $158,795 - $254,865
-23,318 Reduced 2.72%
834,260 $5.69 Million
Q1 2021

May 17, 2021

BUY
$6.14 - $8.31 $1.73 Million - $2.34 Million
281,456 Added 48.85%
857,578 $6.06 Million
Q4 2020

Feb 12, 2021

SELL
$4.58 - $7.14 $513,527 - $800,565
-112,124 Reduced 16.29%
576,122 $3.61 Million
Q3 2020

Nov 12, 2020

BUY
$4.19 - $6.69 $21,549 - $34,406
5,143 Added 0.75%
688,246 $3.72 Million
Q2 2020

Aug 14, 2020

SELL
$2.97 - $5.22 $58,298 - $102,463
-19,629 Reduced 2.79%
683,103 $3.57 Million
Q1 2020

May 12, 2020

SELL
$2.67 - $4.97 $24,999 - $46,534
-9,363 Reduced 1.31%
702,732 $2.21 Million
Q4 2019

Feb 14, 2020

BUY
$2.93 - $4.5 $1.57 Million - $2.4 Million
534,222 Added 300.34%
712,095 $2.87 Million
Q3 2019

Nov 15, 2019

BUY
$3.08 - $5.76 $34,991 - $65,439
11,361 Added 6.82%
177,873 $768,000
Q2 2019

Aug 14, 2019

SELL
$3.47 - $6.32 $7,852 - $14,302
-2,263 Reduced 1.34%
166,512 $664,000
Q1 2019

May 14, 2019

SELL
$5.36 - $7.24 $62,899 - $84,961
-11,735 Reduced 6.5%
168,775 $905,000
Q4 2018

Feb 13, 2019

SELL
$4.8 - $11.6 $14,904 - $36,018
-3,105 Reduced 1.69%
180,510 $926,000
Q3 2018

Nov 13, 2018

BUY
$9.05 - $10.95 $64,046 - $77,493
7,077 Added 4.01%
183,615 $1.78 Million
Q2 2018

Aug 15, 2018

BUY
$10.2 - $13.9 $1.8 Million - $2.45 Million
176,538 New
176,538 $1.8 Million

Others Institutions Holding PRTK

About Paratek Pharmaceuticals, Inc.


  • Ticker PRTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,862,500
  • Description
  • Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...
More about PRTK
Track This Portfolio

Track Granahan Investment Management, LLC Portfolio

Follow Granahan Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granahan Investment Management, LLC with notifications on news.